Previous 10 | Next 10 |
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is one of today's top gainers. The company's shares have moved 10.99% on the day to $282.88. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for ...
2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...
2024-06-10 21:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for MDGL on June 10, 2024 07:10PM ET. MDGL was trading at $254.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 8 - Buy, 1 ...
2024-06-10 09:45:00 ET Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver disease and obesity, and, until recently, despite the...
2024-06-09 08:47:48 ET Summary Eli Lilly's tirzepatide shows potential in resolving metabolic dysfunction-associated steatohepatitis without worsening fibrosis. GLP-1 drugs pose a serious threat to Madrigal's Rezdiffra, potentially dominating the MASH market. Madrigal's financ...
2024-06-07 11:15:07 ET Summary Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has become more volatile due to competition from other ...
2024-06-07 07:21:34 ET Summary Galectin Therapeutics is focused on developing therapies that target galectin proteins related to conditions such as metabolic dysfunction-associated steatohepatitis, cirrhosis, and cancer. Its leading drug candidate, belapectin, is a galectin-3 inhi...
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis Noninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% o...
2024-06-05 08:10:19 ET More on Eli Lilly Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly CFO Anat Ashkenaz...
CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET. The presentati...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...
2024-06-15 09:45:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, ...